Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer

Inclusion Criteria: * Patients must have histologically confirmed thyroid cancer that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective. * Patients may have received multiple treatments of radioactive iodine, one prior biologic treatment, and at least half of the patients will have had no prior chemotherapy for metastatic disease. At least 3 weeks must have elapsed since prior treatment. * Measurable disease defined as at least one malignant lesion that can be accurately and serially measured in at least one dimension (longest diameter to be recorded), using a caliper (diameter \> 10 mm) for superficial cutaneous disease, or using contrast-enhanced CT or spiral CT (diameter \> 20 mm) for visceral or nodal/soft tissue disease. * ECOG performance status \< 2 (Appendix 1). * Life expectancy greater than 3 months. * Adequate organ function that has been determined within 7 days prior to enrollment, defined as:Leucocyte count \> 3,000/uL; Absolute neutrophil count (ANC) \> 1,500/mm3, platelets \> 100,000/mm3, and hemoglobin \> 9 g/dl; Serum creatinine \< 1.5 times ULN, or 24-hour creatinine clearance \> 75 cc/min. (Note: creatinine clearance need not be determined if the baseline serum creatinine is within normal limits); Serum bilirubin \< 1.5 times ULN; serum glutamyloxaloacetic transaminase (SGOT) \< 2.5 ULN; alkaline phosphatase \< 2.5 times ULN; PT-INR/PTT \< 1.5 x upper limit of normal. * Intellectua…